Novel drug approved for multiple myeloma
the ONA take:
The U.S. Food and Drug Administration has approved Farydak (panobinostat) in combination with bortezomib and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior standard therapies, including an immunomodulatory agent like thalidomide or lenalidomide and bortezomib.
“Farydak has a new mechanism of action that distinguishes it from prior drugs approved to treat multiple myeloma, making it a potentially attractive candidate agent for the treatment of multiple myeloma,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Farydak’s approval is particularly important because it has been shown to slow the progression of multiple myeloma.”
The most common side effects associated with Farydak were diarrhea, nausea, decreased appetite, peripheral edema, vomiting, tiredness, and weakness. The most common laboratory abnormalities were hypokalemia, hypophosphatemia, hyponatremia, anemia, thrombocytopenia, and leukopenia.
According to the American Cancer Society's estimates, there will be about 26,850 new cases of multiple myeloma in the United States in 2015 and about 11,240 deaths.
The FDA has approved Farydak (panobinostat) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.
Sign Up for Free e-newsletters
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|